Skip to main content
Clinical Trials/ACTRN12609000672257
ACTRN12609000672257CompletedPhase 1

A Phase 1 Study of Epidermal Growth Factor Receptor (EGFR) Targeted, Paclitaxel Loaded EnGeneIC Delivery Vehicles in Patients with Advanced Solid Tumours

EnGeneIC Pty Ltd0 sites32 target enrollmentStarted: August 6, 2009Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
32

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Non-randomised trial
Primary Purpose
Treatment
Masking
Open (masking not used)

Eligibility Criteria

Ages
18 Years to o limit (—)
Sex
All

Inclusion Criteria

  • Patients with advanced solid tumours that are metastatic or unresectable. Patients must have tumour types known to express EGFR.

Exclusion Criteria

  • Previous treatment with taxanes, treatment with EGFR inhibitor or other chemotherapy or radiotherapy in past 30 days, salmonella vaccination in past 12 months, hypersensitivity to monoclonal antibodies or taxanes, uncontrolled brain metastases

Investigators

Similar Trials

A Phase 1 Study of Epidermal Growth Factor... | Clinical Trial